[Treatment of chronic @entity943 with the new class Ic anti- XXXX agent diprafenon--results of long-term therapy].

@entity1 @entity227 @entity713 @entity1295 @entity72573 @entity6237 @entity2778 @entity10 @entity943 @entity2779
@entity72573 is a new antiarrhythmic drug with a dominant local anaesthetic action and an additional beta-sympathicolytic activity. In this study, the results of long-term treatment (8 months on average) obtained from 27 @entity1 with chronic @entity943 are reported. Before @entity72573 , all @entity1 were treated unsuccessfully with @entity6237 , @entity2779 , @entity2778 , combined @entity2778 / @entity6237 and @entity2778 / @entity2779 , and another two to six antiarrhythmic agents. Following @entity72573 (300-600 mg/24 h), a substantial reduction in arrhythmic activity (greater than or equal to 80%; Lown classification less than or equal to II) was achieved in 21 cases. In 12 @entity1 , side effects ( @entity1295 , @entity10 , @entity227 , dizziness and heartburn) were apparent. @entity72573 had to be discontinued in five @entity1 , because of these side effects. At dosages greater than or equal to 450 mg/24 h, the PQ interval was significantly lengthened, and QRS duration prolonged. In one @entity1 , an @entity713 III degree developed. In another case, SGOT and SGPT increased significantly; this increase was reversed after the drug was discontinued. Despite these side effects, further clinical evaluation of the compound seems promising, as the antiarrhythmic potency of @entity72573 is very strong and superior to that of @entity2779 with respect to the required doses.
